Hyperfine vs Nano-X Imaging
HYPR and NNOX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HYPR and NNOX compare
Hyperfine grew revenue faster over the last twelve months (80.0% versus 15.4% for Nano-X Imaging).
Hyperfine keeps more of each dollar of sales as profit, with a net margin of −156% compared with −576% at Nano-X Imaging.
Hyperfine scores higher on the StockData Score (7 against 5 for Nano-X Imaging), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HYPR | NNOX |
|---|---|---|
| Size and price | ||
| Market cap | $66.7M | – |
| Share price | $0.629 | $0.322 |
| Change, 1 year | −42.8% | −89.4% |
| Change, 5 years | −93.7% | −98.3% |
| Beta (5Y) | 1.03 | 1.37 |
| Employees | 102 | 197 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.5× | – |
| P/B | 2.1× | – |
| FCF yield | −41.8% | – |
| Fair value | $0.774 | – |
| Margin of safety | 18.7% | – |
| Growth | ||
| Revenue growth (TTM) | 80.0% (better) | 15.4% |
| Revenue growth, 5Y average | 115% | – |
| Profitability | ||
| Gross margin | 52.6% (better) | −98.2% |
| Operating margin | −168% (better) | −601% |
| Net margin | −156% (better) | −576% |
| FCF margin | −146% (better) | −346% |
| Return on equity | −102% | −63.6% (better) |
| Return on invested capital | −403% | −59.5% (better) |
| Financial health | ||
| Debt / equity | 0.42 | 0.04 (better) |
| Current ratio | 5.10 (better) | 2.84 |
| Altman Z-score | −7.63 | – |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 20.6% | 13.9% |
| Held by insiders | 18.1% | 10.4% |
| Insider net buying, 12 months | −$91.9K | $190K (better) |
| Short interest, % of float | 4.5% | 9.3% |
Go deeper
- HYPR stock overview
- HYPR income statement
- HYPR valuation and score
- NNOX stock overview
- NNOX income statement
- NNOX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.